Guardant Health receives FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer's Veppanu (vepdegestrant) for patients with ER+/Her2- advanced breast cancer with ESR1 mutations

Published: 2026-05-04 08:30:00 ET GH

Published on 05/04/2026 at 08:30 am EDT